FDA grants accelerated approval to lifileucel for melanoma

The FDA has granted accelerated approval to lifileucel for the treatment of unresectable or metastatic melanoma, according to the agency's announcement. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma.¹

The document provided does not include additional details such as the specific indication criteria, dosing regimen, clinical trial data supporting the approval, or the date of the approval decision. It also does not specify the confirmatory trial requirements typically associated with accelerated approvals, nor does it name the manufacturer or sponsor of lifileucel.

Readers seeking fuller clinical and regulatory detail, including trial endpoints, patient population specifics, and post-marketing requirements, would need to consult the full FDA announcement or related regulatory filings, as this record contains only the headline statement of the approval itself.